Neoprobe names new VP of pharmaceutical research and clinical development

Dr Cope has most recently served as the assistant director for research and head of program research development for The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and The Richard J Solove Research Institute.

Dr Cope has received his BSc from the Delaware Valley College of Science and Agriculture, his MS from Millersville University of Pennsylvania and his PhD from the University of Connecticut.

David Bupp, president and CEO of Neoprobe, said: “Fred is joining us at an exciting point in our corporate development as we work through the pivotal clinical trials and prepare for the regulatory submissions to support marketing clearance for Lymphoseek and as we make visible progress in reinvigorating our development activities related to RIGScan CR.”